Logo image of IOVA

IOVANCE BIOTHERAPEUTICS INC (IOVA) Stock Fundamental Analysis

USA - NASDAQ:IOVA - US4622601007 - Common Stock

1.97 USD
+0.02 (+1.03%)
Last: 10/31/2025, 8:00:02 PM
1.995 USD
+0.03 (+1.27%)
Pre-Market: 11/3/2025, 6:28:39 AM
Fundamental Rating

3

We assign a fundamental rating of 3 out of 10 to IOVA. IOVA was compared to 534 industry peers in the Biotechnology industry. While IOVA seems to be doing ok healthwise, there are quite some concerns on its profitability. While showing a medium growth rate, IOVA is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year IOVA has reported negative net income.
In the past year IOVA has reported a negative cash flow from operations.
IOVA had negative earnings in each of the past 5 years.
In the past 5 years IOVA always reported negative operating cash flow.
IOVA Yearly Net Income VS EBIT VS OCF VS FCFIOVA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -100M -200M -300M -400M

1.2 Ratios

IOVA's Return On Assets of -42.97% is in line compared to the rest of the industry. IOVA outperforms 55.99% of its industry peers.
IOVA has a Return On Equity of -55.82%. This is in the better half of the industry: IOVA outperforms 63.30% of its industry peers.
Industry RankSector Rank
ROA -42.97%
ROE -55.82%
ROIC N/A
ROA(3y)-52.47%
ROA(5y)-47.04%
ROE(3y)-69.19%
ROE(5y)-60.44%
ROIC(3y)N/A
ROIC(5y)N/A
IOVA Yearly ROA, ROE, ROICIOVA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -20 -40 -60

1.3 Margins

IOVA has a better Gross Margin (20.60%) than 72.66% of its industry peers.
The Profit Margin and Operating Margin are not available for IOVA so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 20.6%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
IOVA Yearly Profit, Operating, Gross MarginsIOVA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -10K -20K -30K

More info and screens

6

2. Health

2.1 Basic Checks

IOVA does not have a ROIC to compare to the WACC, probably because it is not profitable.
IOVA has more shares outstanding than it did 1 year ago.
The number of shares outstanding for IOVA has been increased compared to 5 years ago.
IOVA has a better debt/assets ratio than last year.
IOVA Yearly Shares OutstandingIOVA Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M
IOVA Yearly Total Debt VS Total AssetsIOVA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M

2.2 Solvency

IOVA has an Altman-Z score of -2.80. This is a bad value and indicates that IOVA is not financially healthy and even has some risk of bankruptcy.
The Altman-Z score of IOVA (-2.80) is comparable to the rest of the industry.
There is no outstanding debt for IOVA. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -2.8
ROIC/WACCN/A
WACC8.74%
IOVA Yearly LT Debt VS Equity VS FCFIOVA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M -200M 400M 600M

2.3 Liquidity

A Current Ratio of 3.27 indicates that IOVA has no problem at all paying its short term obligations.
IOVA has a Current ratio of 3.27. This is in the lower half of the industry: IOVA underperforms 61.42% of its industry peers.
A Quick Ratio of 2.89 indicates that IOVA has no problem at all paying its short term obligations.
IOVA has a Quick ratio of 2.89. This is in the lower half of the industry: IOVA underperforms 63.48% of its industry peers.
Industry RankSector Rank
Current Ratio 3.27
Quick Ratio 2.89
IOVA Yearly Current Assets VS Current LiabilitesIOVA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M

More info and screens

4

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 26.35% over the past year.
IOVA shows a strong growth in Revenue. In the last year, the Revenue has grown by 636.96%.
EPS 1Y (TTM)26.35%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%2.94%
Revenue 1Y (TTM)636.96%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%92.73%

3.2 Future

The Earnings Per Share is expected to grow by 19.94% on average over the next years. This is quite good.
Based on estimates for the next years, IOVA will show a very strong growth in Revenue. The Revenue will grow by 45.14% on average per year.
EPS Next Y11.91%
EPS Next 2Y22.78%
EPS Next 3Y23%
EPS Next 5Y19.94%
Revenue Next Year66.21%
Revenue Next 2Y61.35%
Revenue Next 3Y55.28%
Revenue Next 5Y45.14%

3.3 Evolution

IOVA Yearly Revenue VS EstimatesIOVA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 500M 1B 1.5B
IOVA Yearly EPS VS EstimatesIOVA Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 0 1 -1 -2

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for IOVA. In the last year negative earnings were reported.
Also next year IOVA is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
IOVA Price Earnings VS Forward Price EarningsIOVA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80 100

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
IOVA Per share dataIOVA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1

4.3 Compensation for Growth

A more expensive valuation may be justified as IOVA's earnings are expected to grow with 23.00% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y22.78%
EPS Next 3Y23%

More info and screens

0

5. Dividend

5.1 Amount

IOVA does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

IOVANCE BIOTHERAPEUTICS INC

NASDAQ:IOVA (10/31/2025, 8:00:02 PM)

Premarket: 1.995 +0.03 (+1.27%)

1.97

+0.02 (+1.03%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-07 2025-08-07/amc
Earnings (Next)11-06 2025-11-06/bmo
Inst Owners61.39%
Inst Owner Change-0.81%
Ins Owners0.36%
Ins Owner Change8.52%
Market Cap712.84M
Revenue(TTM)241.53M
Net Income(TTM)-389921000
Analysts75.56
Price Target9.28 (371.07%)
Short Float %25.21%
Short Ratio7.62
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-30.58%
Min EPS beat(2)-47.45%
Max EPS beat(2)-13.7%
EPS beat(4)2
Avg EPS beat(4)-12.08%
Min EPS beat(4)-47.45%
Max EPS beat(4)8.26%
EPS beat(8)5
Avg EPS beat(8)-5.2%
EPS beat(12)9
Avg EPS beat(12)3.29%
EPS beat(16)10
Avg EPS beat(16)2.22%
Revenue beat(2)0
Avg Revenue beat(2)-28.3%
Min Revenue beat(2)-40.82%
Max Revenue beat(2)-15.78%
Revenue beat(4)1
Avg Revenue beat(4)-12.53%
Min Revenue beat(4)-40.82%
Max Revenue beat(4)6.69%
Revenue beat(8)2
Avg Revenue beat(8)-30.92%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-9%
EPS NQ rev (1m)0%
EPS NQ rev (3m)7.34%
EPS NY rev (1m)0%
EPS NY rev (3m)0.87%
Revenue NQ rev (1m)-0.77%
Revenue NQ rev (3m)-9.19%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-9.9%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 2.95
P/FCF N/A
P/OCF N/A
P/B 1.02
P/tB 1.77
EV/EBITDA N/A
EPS(TTM)-1.23
EYN/A
EPS(NY)-0.64
Fwd EYN/A
FCF(TTM)-0.89
FCFYN/A
OCF(TTM)-0.84
OCFYN/A
SpS0.67
BVpS1.93
TBVpS1.11
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -42.97%
ROE -55.82%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 20.6%
FCFM N/A
ROA(3y)-52.47%
ROA(5y)-47.04%
ROE(3y)-69.19%
ROE(5y)-60.44%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0.27
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 39.84%
Cap/Sales 8.33%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.27
Quick Ratio 2.89
Altman-Z -2.8
F-Score5
WACC8.74%
ROIC/WACCN/A
Cap/Depr(3y)104.04%
Cap/Depr(5y)1124.91%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)26.35%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%2.94%
EPS Next Y11.91%
EPS Next 2Y22.78%
EPS Next 3Y23%
EPS Next 5Y19.94%
Revenue 1Y (TTM)636.96%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%92.73%
Revenue Next Year66.21%
Revenue Next 2Y61.35%
Revenue Next 3Y55.28%
Revenue Next 5Y45.14%
EBIT growth 1Y12.2%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year9.88%
EBIT Next 3Y17.85%
EBIT Next 5YN/A
FCF growth 1Y8.78%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y9.45%
OCF growth 3YN/A
OCF growth 5YN/A

IOVANCE BIOTHERAPEUTICS INC / IOVA FAQ

What is the fundamental rating for IOVA stock?

ChartMill assigns a fundamental rating of 3 / 10 to IOVA.


Can you provide the valuation status for IOVANCE BIOTHERAPEUTICS INC?

ChartMill assigns a valuation rating of 1 / 10 to IOVANCE BIOTHERAPEUTICS INC (IOVA). This can be considered as Overvalued.


Can you provide the profitability details for IOVANCE BIOTHERAPEUTICS INC?

IOVANCE BIOTHERAPEUTICS INC (IOVA) has a profitability rating of 1 / 10.


What is the expected EPS growth for IOVANCE BIOTHERAPEUTICS INC (IOVA) stock?

The Earnings per Share (EPS) of IOVANCE BIOTHERAPEUTICS INC (IOVA) is expected to grow by 11.91% in the next year.